A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers

Completed · Phase 1 · Has a placebo group

Conditions studied: Irritable Bowel Syndrome (IBS)

In brief

This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, retards the emptying of the colon and increases total colonic transit time.

Key facts

Study ID

NCT00401479

Run by

GlaxoSmithKline

People needed

36

Starts

2006-10-01

Last updated by the study team

2008-10-16

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subjects with no evidence of current or past history suggestive of gastrointestinal disease or disorder or medical illness that could compromise interpretation of the study.
• no clinically significant laboratory results collected at the screening visit
• men: body weight greater than or equal to 50kg (110 lbs)
• women: body weight greater than or equal to 45kg (100 lbs)
• BMI between 18.5 - 35 kg/m2

You may not qualify if…

• Females who are nursing or pregnant.
• history of inflammatory bowel disease
• history of gastric ulcers within 12 months of signing the informed consent form
• tobacco users

Where it is running

• GSK Investigational Site — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.